Drug_Name,STUDYID,YEAR,Country,Dataset,Patient_Count,Median_Age,Female_Percentage,Male_Percentage,Median_BMI,Smoking_History_Yes_Percentage,Total_ADL_Independence_Percentage,LHRH_Use_Percentage,Tumor_Stage_T1_Percentage,Tumor_Stage_T2_Percentage,Tumor_Stage_T3_Percentage,Tumor_Stage_T4_Percentage,Nodal_Stage_N0_Percentage,Nodal_Stage_N1_Percentage,Nodal_Stage_N2_Percentage,Nodal_Stage_N3_Percentage,Stage_I_Percentage,Stage_II_Percentage,Stage_III_Percentage,Diabetes_Mellitus_Percentage,Congestive_Heart_Failure_Percentage,Stroke_Percentage,Atrial_Fibrillation_Percentage,Myocardial_Infarction_Percentage,Neoadjuvant_Chemotherapy_Received_Percentage,Adjuvant_Chemotherapy_Received_Percentage,Postoperative_RT_Received_Percentage,Common_Neoadjuvant_Regimen_1,Common_Neoadjuvant_Regimen_2,Common_Adjuvant_Regimen_1,Common_Adjuvant_Regimen_2,Tamoxifen_Percentage,Letrozole_Percentage,Anastrozole_Percentage,Antidiarrheal_Agent_Probiotics_Percentage,Antiemetic_Agent_Percentage,Painkiller_Antipyretic_Percentage,Beds_Less_Than_200_Percentage,Beds_200_To_499_Percentage,Beds_Greater_Or_Equal_To_500_Percentage,Designated_Cancer_Hospital_Percentage,Months_Between_Surgery_And_Index_Date
Zoledronic Acid,ZA2023-001,2023,USA,MDV,350,68,62,38,27.5,28,85,12,15,35,30,20,55,25,15,5,20,40,30,18,7,3,9,4,10,45,55,AC,Taxol,CMF,Taxol,30,25,20,15,60,70,15,45,40,60,2
Zoledronic Acid,ZA2022-002,2022,Canada,Claim Database,420,72,58,42,28.1,32,78,15,12,38,32,18,52,28,14,6,18,42,32,20,8,4,10,5,12,48,58,EC,Docetaxel,AC,Docetaxel,32,23,18,17,62,72,18,42,40,62,3
Zoledronic Acid,ZA2023-003,2023,UK,MDV,280,65,65,35,26.8,25,90,10,18,32,28,22,60,22,12,6,22,38,30,16,6,2,8,3,8,42,52,FEC,CMF,FEC,CMF,35,20,15,12,58,68,12,48,40,58,2.5
Zoledronic Acid,ZA2022-004,2022,Australia,Claim Database,480,70,60,40,27.9,30,82,13,14,36,31,19,54,26,13,7,19,41,31,19,7,3,9,4,11,46,56,AC-T,FEC,AC-T,FEC,31,24,19,16,61,71,17,43,40,61,2.8
